argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

Rhea-AI Summary

argenx, a global immunology company, will host a conference call on July 27, 2023, to discuss its half year 2023 financial results and provide a second quarter business update. The webcast can be accessed on the argenx website. Dial-in numbers are provided for participants.

July 20, 2023

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET (8:30 am ET) to discuss its half year 2023 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                 1 888 415 4250
Japan                        81 3 4578 9081
Switzerland                41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Erin Murphy
emurphy@argenx.com

Investors:

Alexandra Roy (US)
ARoy@argenx.com

Lynn Elton (EU)
LElton@argenx.com

FAQ

When will argenx host the conference call?

argenx will host the conference call on Thursday, July 27, 2023.

What is the purpose of the conference call?

The conference call will discuss argenx's half year 2023 financial results and provide a second quarter business update.

Where can I access the webcast of the conference call?

The webcast can be accessed on the Investors section of the argenx website at argenx.com/investors.

How long will the webcast be available?

The webcast will be available on the argenx website for approximately one year following the presentation.

What are the dial-in numbers for the conference call?

Participants can use the following dial-in numbers: Belgium 32 800 50 201, France 33 800 943355, Netherlands 31 20 795 1090, United Kingdom 44 800 358 0970, United States 1 888 415 4250, Japan 81 3 4578 9081, Switzerland 41 43 210 11 32.